摘要
目的探讨美托洛尔和卡维地洛治疗慢性心力衰竭的临床疗效及安全性。方法选取2014年11月至2015年12月于我院进行治疗的慢性心力衰竭患者115例,按照随机数字表法分为A组58例,B组57例,两组分别使用美托洛尔及卡维地洛进行治疗。对两组治疗前后心功能指标、临床疗效及不良反应发生情况比较。结果治疗后,两组患者LVEF明显升高,LVEDD及LVESD均明显下降,较治疗前差异明显(P<0.05),且B组变化幅度更加明显(P<0.05)。B组总有效率明显高于A组,且不良反应发生率明显低于A组(P<0.05)。结论与美托洛尔相较,卡维地洛对慢性心力衰竭具有更好的临床疗效及安全性。
Objective To investigate the clinical efficacy and safety of metoprolol and carvedilol in treatment of chronic heart failure. Methods One hundred and fifteen cases of chronic heart failure treated in our hospital fiom November 2014 to December 2015 were collected and devided into group A （58 cases, metoprolol treatment） and group B （57 cases, carvedilol treatment） according to the random number table method. Cardiac function, clinical efficacy and adverse reactions before and after treatment of two groups were compared. Results After treatment, the two groups of patients with LVEF significantly increased, LVEDD and LVESD were significantly decreased, the difference was statistically significant （P〈0.05）, the change range of B group was more significant （P〈0.05）. The total effective rate of group B was significantly higher than that of group A, the incidence of adverse reactions was significantly lower than that of group A. Conclusion The clinical efficacy and safety of carvedilol for chronic heart failure is better, which is worth of clinical application.
出处
《临床医学研究与实践》
2016年第22期98-99,共2页
Clinical Research and Practice
